1198787-40-4

Upstream product

• 400-31-7 1,1,1-trifluoro-4-methyl-pent-3-en-2-one 
• 1198785-31-7 2-(1,1-dimethyl-3-trifluoromethyl-3-trimethylsilanyloxyhex-5-ynyl)benzamide 
• 1198785-30-6 2-(1,1-dimethyl-3-trifluoromethyl-3-trimethylsilanyloxy-hex-5-ynyl)benzoic acid 
• 1198785-29-3 2-(3-hydroxy-1,1-dimethyl-3-trifluoromethylhex-5-ynyl)benzoic acid 
• 1198785-28-2 5,5-dimethyl-3-prop-2-ynyl-3-trifluoromethyl-1,3,4,5-tetrahydrobenzo[c]oxepin-1-ol 
• 1198785-78-2 4-(2-[1,3]-dioxinan-2-yl-4-flourophenyl)-1,1,1-trifluoro-4-methylpentan-2-one 
• 1198785-60-2 4-(2-[1,3]dioxan-2-ylphenyl)-1,1,1-trifluoro-4-methylpentan-2-one 
• 1307770-99-5 2-(2-bromo-5-fluorophenyl)-1,3-dioxane 
• 61568-53-4 2-(ortho-bromophenyl)-1,3-dioxane 

Relevant academic research and scientific papers

Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate

A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.